Montelukast Unimark (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Unimark, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed in the maintenance treatment of asthma and to relieve symptoms of allergic rhinitis in adults and children.

GNH USA supplies Montelukast Unimark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Montelukast Unimark, a leukotriene receptor antagonist, is used to manage conditions driven by leukotriene‑mediated inflammation.

- Asthma: improves long‑term control and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: lessens airway narrowing that occurs after physical activity.

Adverse reactions may occur with any medication. The following are reported for Montelukast Unimark.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Mood changes including depression or suicidal thoughts - Elevated liver enzymes or hepatic dysfunction - Severe skin reactions such as Stevens‑Johnson syndrome

Before prescribing Montelukast Unimark, clinicians should consider several safety aspects.

- Pregnancy: consult a healthcare professional as safety data are limited. - Breastfeeding: weigh potential benefits against unknown risks. - Pediatric use: follow prescriber guidance for age‑appropriate dosing. - Drug interactions: review all concomitant medicines for possible effects. - Renal or hepatic impairment: dose adjustment may be required. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Montelukast may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) can markedly lower montelukast exposure. - Phenobarbital may reduce plasma concentrations and diminish efficacy.

Moderate Interactions (Monitor Closely): - Certain antidepressants (e.g., fluoxetine) may increase risk of neuropsychiatric events. - Phenylbutazone can raise montelukast levels. - Warfarin may experience altered anticoagulant effect, requiring INR monitoring.